Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals - (Yahoo Finance via NewsPoints Desk)

  • Novartis and Lonza separately inked deals to expand their portfolio of biosimilar therapies, as reported Yahoo!Finance Tuesday.

  • Specifically, Novartis' Sandoz unit licenced a biosimilar version of Biogen's multiple sclerosis drug Tysabri from Polpharma Biologics, while Lonza entered into a contract to provide drug substance production for Celltrion's Remsima, a biosimilar version of Johnson & Johnson's Remicade.

  • Lonza CEO Marc Funk said said the deal would provide Celltrion "the flexible capacity and agile teams it needs to respond to evolving market demand."

  • Meanwhile, Pierre Bourdage, Sandoz's interim biopharmaceuticals head, commented "biosimilars create competition and cost savings, which are proven to make room in healthcare systems to treat more patients."

  • "The acceptance for cheaper MS medicines will be great, because around half of all patients cannot afford them," ZKB analyst Michael Nawrath stated.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.